ArticleLeukemia2025

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.

Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.